Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Mycobacterium vaccae for COVID-19 pneumonia
ChiCTR2000030016Phase 4Recruiting
- Sponsor
- Guangxi Medical University
- Start
- Feb 2020
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of mycobacterium vaccae in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Guangxi Medical University. Primary endpoints: Viral negative-transforming time, 30-day cause-specific mortality and 7 more. Started Feb 2020; status: recruiting.
02
Drugs
mycobacterium vaccae
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2000030016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000030016.